您好，欢迎来到化工原料网！ [登录] [免费注册]
化工原料网
发布求购
位置：首页 > 产品库 > C14 Ceramide(d18:1/14:0)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
C14 Ceramide(d18:1/14:0)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
C14 Ceramide(d18:1/14:0)图片
CAS NO:34227-72-0
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
Cas No.34227-72-0
别名十四酰鞘氨醇,Cer(d18:1/14:0)
化学名N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-tetradecanamide
Canonical SMILESOC[C@H](NC(CCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCCCC
分子式C32H63NO3
分子量509.9
溶解度DMF: 0.15 mg/mL
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

C14 Ceramide is an endogenous ceramide generated by ceramide synthase 6. [1] During nutrient-deprivation-induced necroptosis in MEF cells, C14 ceramide levels increase in a time-dependent manner. [2] C14 ceramide plasma levels were reduced in obese patients with or without diabetes following a 12-week supervised exercise training program, correlating positively with weight and fat loss and negatively with an increase in insulin sensitivity. [3] In contrast, plasma levels were higher in Parkinson's disease patients with dementia than those without dementia and higher levels were correlated with deficits in memory.[4]

Reference:
[1]. Grosch, S., Schiffmann, S., and Geisslinger, G. Chain length-specific properties of ceramides. Prog. Lipid Res. 51(1), 50-62 (2012).
[2]. Sundaram, K., Mather, A.R., Marimuthu, S., et al. Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death. Biochem J. 473(6), 43-55 (2016).
[3]. Kasumov, T., Solomon, T.P., Hwang, C., et al. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring) 23(7), 1414-1421 (2015).
[4]. Xing, Y., Tang, Y., Zhao, L., et al. Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson’s disease dementia. J. Neurol. Sci. 370, 82-87 (2016).